NYSE: TAROTaro Pharmaceutical Industries Ltd Stock
$24.32+0.02 (+0.08%)
Updated Mar 31, 2023
TARO Price
$24.32
Fair Value Price
N/A
Market Cap
$914.12M
52 Week Low
$22.89
52 Week High
$43.58
P/E
14.06x
P/B
0.54x
P/S
1.98x
PEG
N/A
Dividend Yield
N/A
Revenue
$569.41M
Earnings
$64.98M
Gross Margin
49.5%
Operating Margin
11.5%
Profit Margin
11.4%
Debt to Equity
0.24
Operating Cash Flow
-$188M
Beta
0.46
Next Earnings
May 24, 2023
Ex-Dividend
N/A
Next Dividend
N/A
TARO Overview
Taro Pharmaceutical Industries Limited manufactures and markets prescription and over-the-counter drugs covering various therapeutic categories in the U.S. and internationally. It provides its products as capsules, creams, drops, emulsions, gels/gel kits, granules, injectables, oils, ointments,powders for solution, suppositories, solutions for infusion, sprays, suspensions, and syrups. Taro Pharmaceutical was founded in 1950 and is based in Haifa, Israel.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TARO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TARO was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TARO is good value based on its earnings relative to its share price (14.06x), compared to the US market average (22.13x)
P/E vs Market Valuation
TARO is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more TARO due diligence checks available for Premium users.
Be the first to know about important TARO news, forecast changes, insider trades & much more!
TARO News
Valuation
TARO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
14.06x
Industry
18.12x
Market
22.13x
TARO is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
TARO is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
TARO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.54x
Industry
1.83x
TARO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TARO's financial health
Profit margin
Revenue
$130.5M
Net Income
-$2.8M
Profit Margin
-2.2%
TARO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TARO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.1B
Liabilities
$401.0M
Debt to equity
0.24
TARO's short-term assets ($1.36B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TARO's short-term assets ($1.36B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TARO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TARO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$20.4M
Investing
-$70.8M
Financing
$0.0
TARO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TARO vs Pharmaceutical Stocks
Taro Pharmaceutical Industries Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.